Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.

ABSTRACT:

Objectives

A platinum/etoposide doublet is standard first-line therapy for poorly differentiated neuroendocrine carcinoma (PD NEC); however, evidence to guide treatment beyond first-line regimens is lacking. This study aimed to evaluate the efficacy of second-line regimens in PD NEC.

Methods

We performed a retrospective analysis of patients treated with second-line chemotherapy for PD NEC. Inclusion criteria were previous first-line therapy with platinum/etoposide, extrapulmonary PD NEC, and follow-up data. The primary end points were overall survival (OS) and progression-free survival (PFS) after second-line therapy. Secondary end points included OS and PFS from first-line therapy.

Results

Sixty-four patients were included. The median OS from initiation of second-lin

SUBMITTER: McGarrah PW 

PROVIDER: S-EPMC7158760 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature